ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,887 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryZurichDenali Therapeutics CH GmbH
Denali Therapeutics CH GmbH Logo
Verified· 2 sourcesTrust Score
Summary

About the company

Denali Therapeutics CH GmbH is a biopharmaceutical company that discovers, develops and delivers biotherapeutics intended to treat serious diseases affecting the brain and the body. It developed the TransportVehicle™ platform to enable systemic delivery of enzymes, oligonucleotides and antibodies across the blood–brain barrier and is advancing a pipeline for neurodegenerative and lysosomal storage disorders.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Denali Therapeutics CH GmbH

✓ Offered6
Therapeutic drug development
Development of therapeutics for severe diseases, in particular neurodegenerative disorders, lysosomal storage diseases and other severe diseases, from discovery through to clinical development.
TransportVehicle™ platform
Modular platform to cross the blood-brain barrier and to administer enzymes, oligonucleotides and antibodies to the brain and throughout the body.
Clinical studies
Conduct of Phase 1, Phase 2 and Phase 3 studies to assess safety, dosing, efficacy and the benefit-risk profile of investigational therapies.
Early Access Program
Early access to investigational medicines or treatments for patients with severe or life-threatening diseases prior to formal approval.
Grants & sponsorships
Financial support for independent medical education, non-profit organisations and patient advocacy groups in line with the therapeutic focus areas.
Partnerships & collaborations
Collaboration with biopharmaceutical companies, academic institutions, foundations and technology partners to develop and commercialise therapies.
Trust & reputation

ranQ Trust Score of Denali Therapeutics CH GmbH: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Denali Therapeutics CH GmbH has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Denali Therapeutics CH GmbH scores 67.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.64.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Denali Therapeutics CH GmbH scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Denali Therapeutics CH GmbH scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Denali Therapeutics CH GmbH reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Denali Therapeutics CH GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Denali Therapeutics CH GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Denali Therapeutics CH GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Denali Therapeutics CH GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Schützengasse 1
8001 Zurich

At a glance

Legal form
Limited Liability Company
UID
CHE-487.887.939
Founded
2021 · 5 years
Last commercial register change
March 28, 2024
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
88.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    LT
    Linkster Therapeutics AG
    Zurich
    CA
    CUTISS AG
    Schlieren
    OP
    Otsuka Pharmaceutical (Switzerland) GmbH
    Glattbrugg
    SA
    Stallergenes AG
    Dietlikon
    NT
    Numab Therapeutics AG
    Horgen
    JG
    Jantar GmbH
    Horgen
    CA
    CDR-Life AG
    Horgen
    IB
    InterAx Biotech AG
    Schlieren